Amarantus Bioscience Holdings, Inc (OTCPK:AMBS) evaluating four SeD Biomedical assets for potential acquisition into its portfolio of biotechnology assets LOI contemplates capital infusion into Amarantusto assist in restructuring and long term growth plan for building shareholder value Amarantus names four new appointees to its Board of Directors and names Ronald Wei interim-Chief Financial Officer of Amarantus.